Peptides in Veterinary Medicine

Overview

Veterinary medicine was in many ways the first proving ground for peptide therapeutics. Gonadotropin preparations for livestock reproduction, oxytocin for obstetric use in cattle and horses, ACTH for diagnostic testing, and insulin for diabetic companion animals all predate or parallel their widespread human use. Today, the veterinary peptide field continues to evolve, drawing on innovations originating in human medicine (GLP-1 agonists, orexin antagonists) while developing species-specific peptides for animal-specific indications.

This article surveys peptide research in veterinary medicine. See peptide history for how many veterinary peptides shaped the broader field, and peptide regulation for the distinct regulatory frameworks.

Research Directions

Reproductive Peptides in Livestock

Reproductive peptides are the largest category of veterinary peptide use:

• GnRH agonists (buserelin, deslorelin, leuprolide) — induce ovulation timing, synchronize estrus in cattle, manage reproduction in horses and dogs. Deslorelin implants are used for temporary contraception and for treating sexual behavior problems in companion animals.
• hCG and PMSG/eCG — used for superovulation in embryo transfer programs and for ovulation induction.
• Oxytocin — routine use in obstetric and lactation applications in cattle, horses, and other livestock.
• Prostaglandin F2α analogs — not peptides but often used alongside peptide regimens.
• Kisspeptin research — emerging in veterinary reproductive science.

See peptides in fertility for parallel human applications.

Growth Hormone and Somatostatin

• Recombinant bovine somatotropin (rBST) — used in dairy cows in some countries to increase milk yield; banned in EU and Canada.
• Porcine somatotropin — historically used in swine production.
• Somatostatin analogs — used occasionally in companion animals for specific endocrine conditions.

See GH/IGF-1 research.

Insulin Analogs for Companion Animals

Diabetes in dogs and cats is common and frequently requires insulin therapy:

• ProZinc (protamine zinc insulin) — approved for cats.
• Vetsulin/Caninsulin (porcine insulin zinc suspension) — for dogs and cats.
• Human insulin analogs (glargine, detemir) — often used off-label with species-specific dosing.

GLP-1 agonists for feline diabetes are under active investigation, with early data suggesting benefit similar to human type 2 diabetes. See GLP-1 research and peptides in metabolic disease.

Antimicrobial Peptides in Veterinary Use

Antimicrobial peptides (AMPs) are particularly attractive in veterinary medicine given rising antibiotic resistance and regulatory pressure to reduce antibiotic use in animal agriculture:

• Nisin and other bacteriocins — used as feed additives.
• Defensin-based approaches in development.
• Aquaculture AMPs — piscidins and other fish-derived peptides for disease prevention in farmed fish.
• Genetically modified probiotics producing AMPs on demand.

See antimicrobial research and marine peptides.

Behavior and Analgesia

• Canine opioid analgesics — buprenorphine and others used for pain management.
• Deslorelin — can reduce aggression in some species and contexts.
• Oxytocin intranasal — studied for canine social behavior.

Veterinary Vaccines

Peptide vaccines are being explored in:

• Livestock — against foot-and-mouth disease, bovine respiratory disease, and other pathogens.
• Fish aquaculture — where peptide vaccines against bacterial and viral pathogens offer alternatives to antibiotics.
• Companion animals — early-stage development against canine and feline cancers.

See peptide vaccines and peptides in immunology.

Veterinary Oncology

Companion animal oncology is a growing market, and peptide-targeted radionuclide therapy, peptide drug conjugates, and checkpoint-related peptides are emerging. Dogs in particular are valuable models for human cancer research because they develop spontaneous cancers in outbred, heterogeneous populations. See peptides in oncology and peptide drug conjugates.

Equine-Specific Peptides

• Somatostatin analogs for equine Cushing's disease (PPID).
• GnRH vaccines (GonaCon, Improvac) — immunocastration for stallions and boars, avoiding surgical castration.
• Peptide-based wound healing products for equine injuries.

See peptides in wound care for parallel work.

Methodological Considerations

Veterinary peptide research has distinctive features:

• Species-specific pharmacology — receptor sequences and physiology differ across species, so cross-species extrapolation is limited.
• Economic constraints — in livestock, cost per dose is a major factor; peptides must be cheap to produce at scale.
• Welfare considerations — reducing stressful interventions is a design goal.
• Food safety and withdrawal periods — peptide residues and metabolites in food-producing animals must be documented for consumer safety.

See animal models and understanding peptide research. Dogs and cats are also increasingly recognized as translational models for human disease in ways that complement rodent studies.

Regulatory Context

Veterinary peptides are regulated by:

• FDA Center for Veterinary Medicine (CVM) in the United States.
• European Medicines Agency Veterinary Committee.
• Species- and indication-specific approvals that differ substantially from human drug approvals.
• Food safety authorities for residue limits and withdrawal periods.

Some peptides are available only through licensed veterinarians; others are labeled for OTC use. Compounding rules differ from human medicine. See peptide regulation and compounding pharmacies.

Safety and Limitations

Veterinary peptide safety concerns mirror human medicine but with species-specific twists:

• Immunogenicity — cross-species peptides can provoke neutralizing antibodies (classic with porcine insulin in dogs).
• Off-target effects — behavioral or reproductive side effects are relevant across species.
• Residue concerns in food animals.
• Welfare vs productivity tradeoffs — for example, rBST use in dairy herds raises welfare concerns about mastitis.

See peptide safety and purity and testing.

Future of the Field

Emerging directions:

• GLP-1 and dual agonists for obese pets (obesity in companion animals is increasingly recognized as a veterinary health issue).
• AI-designed species-specific peptides — see AI peptide discovery.
• Aquaculture peptides as antibiotic alternatives.
• Peptide vaccines against livestock emerging diseases — including zoonotic threats.
• Peptide-targeted theranostics for companion animal cancers — translating human PRRT approaches.

See future of peptides for broader context.

Summary

Veterinary peptide medicine is a robust and growing field that both benefits from and contributes to human peptide therapeutics. From reproductive management in livestock to insulin therapy for companion animals and emerging GLP-1 applications in pets, peptides are deeply integrated into modern veterinary practice and research.